Crossmark

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)

Crossref DOI link: https://doi.org/10.1007/s10157-017-1427-4

Published Online: 2017-06-28

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kato, Hideki

Nangaku, Masaomi

Hirakata, Hideki

Wada, Takashi

Hayashi, Terumasa

Sato, Hiroshi

Yamazaki, Yasushi

Masaki, Takao

Kagimura, Tatsuo

Yamamoto, Hiroyasu

Hase, Hiroki

Kamouchi, Masahiro

Imai, Enyu

Mizuno, Kyoichi

Iwasaki, Manabu

Akizawa, Tadao

Tsubakihara, Yoshiharu

Maruyama, Shoichi

Narita, Ichiei
Funding

Funding for this research was provided by:

Kyowa Hakko Kirin
License Information

License valid from 2017-06-28

Updates are available Erratum dated 2017-09-05

Click to view Erratum: https://doi.org/10.1007/s10157-017-1461-2